Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + cisplatin + PD-1 inhibitor (TP + PD-1) is a chemo-immunotherapy combination regimen used for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC). The regimen combines two cytotoxic chemotherapy agents—paclitaxel, a taxane that stabilizes microtubules to inhibit mitosis, and cisplatin, a platinum-based agent that causes DNA cross-linking—with a monoclonal antibody targeting the Programmed Death-1 (PD-1) receptor. By blocking the PD-1/PD-L1 pathway, the PD-1 inhibitor restores T-cell mediated anti-tumor activity. This combination is being studied in various clinical settings, including biomarker-guided umbrella trials led by institutions like Sun Yat-sen University, to improve survival outcomes compared to standard chemotherapy alone.
- Other names
- TP regimen plus PD-1 inhibitorpaclitaxel/cisplatin/PD-1 inhibitor
02
Targets
DNAPD-1 (Programmed cell death protein 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + cisplatin + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + PD-1 inhibitor.